Jaguar Health, Inc. (JAGX) Income Statement
JAGX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsJAGX revenue and net income
Where JAGX's revenue goes
2025Each bar shows an amount and its share of revenue. JAGX kept −464.2% of revenue as net income.
JAGX profit margins
JAGX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −1.5% | −1.3% | +4.2% | +46.2% |
| Gross profit | −20.5% | −8.0% | +4.9% | +49.9% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
JAGX quarterly EPS vs estimates
Jaguar Health beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 13, 2026.
JAGX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.5M | $11.7M | $9.8M | $12.0M | $4.3M | $9.4M | $5.8M | $4.4M | $4.4M | $141,523 |
| Cost of revenue | $3.8M | $2.0M | $2.0M | $2.0M | $2.3M | $3.3M | $3.8M | $2.8M | $880,405 | $51,966 |
| Gross profit | $7.7M | $9.7M | $7.7M | $9.9M | $2.0M | $6.1M | $2.0M | $1.7M | $3.5M | $89,557 |
| Research & development | $25.0M | $16.5M | $18.6M | $17.6M | $15.1M | $6.4M | $5.8M | $5.2M | $4.3M | $7.2M |
| Sales, general & admin | $26.0M | $24.0M | $23.0M | $26.7M | $26.0M | $21.0M | $20.4M | $22.1M | $14.3M | $6.5M |
| Total operating expenses | $52.8M | $40.6M | $42.0M | $44.4M | $42.7M | $32.8M | $30.9M | $27.3M | $18.6M | $13.7M |
| Operating income | −$45.1M | −$30.8M | −$34.3M | −$34.4M | −$40.7M | −$26.6M | −$28.9M | −$30.8M | −$34.2M | −$13.6M |
| Interest income | — | — | — | — | — | — | $4.7M | $2.3M | $514,290 | $1.0M |
| Interest expense | $67,000 | $231,000 | $6.4M | $12.7M | $8.4M | $2.8M | $5.7M | $2.6M | $1.2M | $985,549 |
| Income before taxes | −$54.0M | −$39.3M | −$41.9M | −$48.4M | −$52.6M | −$33.8M | −$38.5M | −$32.1M | −$35.1M | −$14.7M |
| Income taxes | −$422,000 | −$759,000 | −$601,000 | −$941,000 | $7.7M | $3.0M | $10,000 | −$1.3M | −$13.2M | $1.1M |
| Net income | −$53.4M | −$38.5M | −$41.3M | −$47.5M | −$52.6M | −$33.8M | −$38.5M | −$32.1M | −$22.0M | −$14.7M |
| EBITDA | −$51.7M | −$36.7M | −$31.5M | −$33.4M | −$42.4M | −$28.7M | −$30.9M | −$28.2M | −$11.1M | −$13.7M |
| EPS (diluted) | −$268.11 | −$12316.50 | −$181682.81 | −$1945004.85 | −$3000023.25 | −$6000033.75 | −$2552.25 | −$53.31 | −$193.93 | −$1428.00 |
| Gross margin | 67.2% | 83.3% | 79.1% | 83.1% | 46.2% | 65.1% | 33.9% | 37.4% | 79.8% | 63.3% |
| Operating margin | −391.9% | −263.8% | −351.3% | −287.8% | −939.1% | −283.9% | −501.3% | −698.0% | −785.3% | −9,599.8% |
| Net margin | −464.2% | −329.3% | −423.1% | −396.9% | −1,213.3% | −360.2% | −667.3% | −727.9% | −503.7% | −10,410.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $20.3M | $3.2M | $3.1M | $3.0M | $2.2M | $3.5M | $3.1M | $2.7M | $2.4M | $2.8M | $2.7M |
| Cost of revenue | $1.0M | $1.2M | $2.2M | $532,000 | $527,000 | $515,000 | $557,000 | $541,000 | $427,000 | $430,000 | $514,000 | $491,000 |
| Gross profit | $194,000 | $19.1M | $1.0M | $2.6M | $2.5M | $1.7M | $3.0M | $2.6M | $2.3M | $1.9M | $2.3M | $2.2M |
| Research & development | $3.3M | $3.9M | $14.3M | $3.7M | $3.3M | $3.7M | $4.5M | $4.0M | $3.7M | $4.3M | $6.1M | $4.3M |
| Sales, general & admin | $4.5M | $5.0M | $5.3M | $6.1M | $7.2M | $7.4M | $6.6M | $5.8M | $5.8M | $5.8M | $5.0M | $6.0M |
| Total operating expenses | $7.8M | $8.9M | $23.7M | $9.8M | $10.5M | $11.1M | $11.1M | $9.8M | $9.5M | $10.1M | $11.1M | $10.3M |
| Operating income | −$7.6M | $10.2M | −$20.4M | −$7.2M | −$8.0M | −$9.4M | −$8.2M | −$7.3M | −$7.2M | −$8.2M | −$8.8M | −$8.1M |
| Interest income | — | — | — | — | — | $56,000 | — | — | — | — | — | — |
| Interest expense | $161,000 | $699,000 | — | $6,000 | — | $56,000 | — | $162,000 | $108,000 | $611,000 | $500,000 | $3.5M |
| Income before taxes | −$12.8M | $8.7M | −$23.2M | −$9.6M | −$10.6M | −$10.6M | −$10.2M | −$10.0M | −$9.6M | −$9.4M | −$7.9M | −$12.3M |
| Income taxes | −$101,000 | $15.7M | — | −$146,000 | — | −$132,000 | — | −$167,000 | −$136,000 | −$139,000 | $304,000 | −$141,000 |
| Net income | −$12.7M | $8.6M | −$23.1M | −$9.5M | −$10.4M | −$10.5M | −$9.9M | −$9.9M | −$9.5M | −$9.2M | −$7.8M | −$12.2M |
| EBITDA | −$12.1M | $9.9M | −$28.7M | −$9.1M | −$10.0M | −$10.1M | −$15.8M | −$9.4M | −$9.1M | −$8.1M | −$6.8M | −$8.2M |
| EPS (diluted) | −$15.70 | — | — | −$219.80 | −$259.26 | −$16.70 | −$4403.00 | −$918.75 | −$3535.00 | −$3459.75 | −$19949.98 | −$36224.96 |
| Gross margin | 15.8% | 94.3% | 32.0% | 82.7% | 82.3% | 76.7% | 84.1% | 82.6% | 84.3% | 81.7% | 81.7% | 81.7% |
| Operating margin | −620.2% | 50.2% | −631.9% | −234.8% | −268.8% | −425.5% | −232.5% | −233.7% | −264.5% | −349.4% | −312.4% | −302.8% |
| Net margin | −1,035.3% | 42.4% | −712.9% | −308.2% | −349.3% | −472.6% | −282.7% | −317.1% | −348.8% | −392.4% | −276.5% | −454.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in JAGX's financial statements (latest annual report filed April 7, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
JAGX financial results
In fiscal year 2025 (ended December 31, 2025), Jaguar Health reported revenue of $11.5 million, down 1.5% from the year before. It had a net loss of $53.4 million, a net profit margin of −464.2%. Diluted earnings per share came to −$268.11. Over five years revenue grew at an average rate of 4.2% a year.
See the JAGX stock overview for the latest quote and news, or the JAGX chart for price history and technical indicators.
JAGX income statement FAQ
What is Jaguar Health's annual revenue?
Jaguar Health reported total revenue of $11.5 million for fiscal year 2025, which ended on December 31, 2025. That was down 1.5% from $11.7 million the previous year.
Is Jaguar Health profitable?
No. Jaguar Health reported a net loss of $53.4 million in fiscal 2025, a net profit margin of −464.2%; its operating margin was −391.9%.
What is Jaguar Health's gross margin?
Jaguar Health's gross margin was 67.2% in fiscal 2025: for every $100 of revenue, Jaguar Health kept $67 after the direct cost of its products and services.
How much does Jaguar Health spend on research and development?
Jaguar Health spent $25.0 million on research and development in fiscal 2025, 216.9% of revenue.
How fast is Jaguar Health growing?
Revenue grew 4.2% a year on average over the last five fiscal years, from $9.4 million to $11.5 million.
What are Jaguar Health's earnings per share?
Jaguar Health earned $-268.11 per diluted share in fiscal 2025, compared with $-12316.50 a year earlier.
When will Jaguar Health report its next earnings?
Jaguar Health is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Jaguar Health's fiscal year end?
Jaguar Health's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 7, 2026.